- Previous Close
3,165.00 - Open
3,115.00 - Bid 3,170.00 x --
- Ask 3,180.00 x --
- Day's Range
3,095.00 - 3,245.00 - 52 Week Range
2,705.00 - 5,640.00 - Volume
61,310 - Avg. Volume
821,843 - Market Cap (intraday)
102.752B - Beta (5Y Monthly) 0.80
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NanoEntek, Inc. engages in the research and development, production, and sale of life-science lab equipment, in vitro diagnostic medical devices, point of care diagnostic devices, and related consumables and solutions in Korea and internationally. It provides FREND system, a fluorescence immunoassay analyzer; BUDDI, a rapid diagnostic test analyzer; rapid diagnostic test items; ADAM-rWBC, a residual white blood cell counters; ADAMII/fluorescence stem cell counter; fluorescence cell counters and cell analyzers; brightfield cell counters; somatic cell counters; live-cell imaging system; and disposable hemocytometers. The company was founded in 1987 and is headquartered in Seoul, South Korea.
www.nanoentek.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Scientific & Technical Instruments
Industry
Recent News: 039860.KQ
View MorePerformance Overview: 039860.KQ
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 039860.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 039860.KQ
View MoreValuation Measures
Market Cap
102.75B
Enterprise Value
69.59B
Trailing P/E
26.89
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.17
Price/Book (mrq)
1.39
Enterprise Value/Revenue
2.28
Enterprise Value/EBITDA
10.89
Financial Highlights
Profitability and Income Statement
Profit Margin
11.77%
Return on Assets (ttm)
0.56%
Return on Equity (ttm)
5.62%
Revenue (ttm)
30.46B
Net Income Avi to Common (ttm)
3.59B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
33.63B
Total Debt/Equity (mrq)
0.63%
Levered Free Cash Flow (ttm)
-4.96B